CCAR1 and colorectal carcinoma: It was found that, when treated with DCLK1 inhibitor, the elevated levels of β‐catenin in nucleus, CCAR1 and DCLK1 in DCLK1‐overexpressing CRC cells were dramatically attenuated (Figure 8A).